Correspondence 0001558370-23-010110 from Kiromic Biopharma, Inc. (KRBP) (CIK 0001792581)
Kiromic Biopharma, Inc. (KRBP) (CIK 0001792581)
Date: May 17, 2023 · CIK: 0001792581 · Accession: 0001558370-23-010110
AI Filing Summary & Sentiment
File numbers found in text: 333-271950
Letter
Kiromic Biopharma, Inc.
7707 Fannin, Suite 140
Houston, TX 77054
May 17, 2023
VIA EDGAR
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Timothy Buchmiller
Re:
Kiromic Biopharma, Inc.
Registration Statement on Form S-1
May 15, 2023
File No. 333-271950
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Kiromic Biopharma, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:00 p.m., Eastern Daylight Time, on Friday, May 19, 2023, or as soon thereafter as possible.
Please notify Jeff Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.
KIROMIC BIOPHARMA, INC.
By:
/s/ Pietro Bersani
Name:
Pietro Bersani
Title:
Chief Executive Officer
-1-
Show Raw Text
CORRESP 1 filename1.htm Kiromic Biopharma, Inc. 7707 Fannin, Suite 140 Houston, TX 77054 May 17, 2023 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Timothy Buchmiller Re: Kiromic Biopharma, Inc. Registration Statement on Form S-1 May 15, 2023 File No. 333-271950 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Kiromic Biopharma, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:00 p.m., Eastern Daylight Time, on Friday, May 19, 2023, or as soon thereafter as possible. Please notify Jeff Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request. KIROMIC BIOPHARMA, INC. By: /s/ Pietro Bersani Name: Pietro Bersani Title: Chief Executive Officer -1-